GLAXOSMITHKLINE has advised of a short-term supply constraint of its Menveo meningococcal ACWY vaccine, after a recent increase in notifications which is driving additional demand.
Menveo is not on the National Immunisation Program, but a number of states and territories have recently introduced Meningococcal W vaccination programs to protect those most at risk of contracting the disease.
GSK said the Meningococcal ACWY vaccine is considered important for those travelling overseas to where the disease burden is greatest, including the so-called 'Meningitis Belt' of sub-Saharan Africa covering 26 countries from Senegal to Ethiopia.
The company said it was prioritising supply of Menveo to the government programs, with forecasts adjusted to meet the anticipated increase in demand.
"We regret the inconvenience this may cause people and their families who want the vaccine, as well as pharmacists and doctors.
"We are working to re-establish supply as a matter of urgency," the company said.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Mar 17